S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:ASLN - ASLAN PHARMACEU/ADR Stock Price, Forecast & News

$1.00
-0.12 (-10.67 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$0.96
Now: $1.01
$1.10
50-Day Range
$0.94
MA: $1.74
$2.19
52-Week Range
$0.35
Now: $1.01
$8.18
Volume189,797 shs
Average Volume296,937 shs
Market Capitalization$32.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.65
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
Read More
ASLAN PHARMACEU/ADR logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
CUSIPN/A
CIKN/A
Phone65-6222-4235

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value($0.02) per share

Profitability

Net Income$-47,070,000.00

Miscellaneous

EmployeesN/A
Market Cap$32.21 million
Next Earnings Date5/4/2020 (Estimated)
OptionableNot Optionable

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.


ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions

How has ASLAN PHARMACEU/ADR's stock been impacted by COVID-19 (Coronavirus)?

ASLAN PHARMACEU/ADR's stock was trading at $1.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ASLN shares have decreased by 36.8% and is now trading at $1.0050. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ASLAN PHARMACEU/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ASLAN PHARMACEU/ADR.

When is ASLAN PHARMACEU/ADR's next earnings date?

ASLAN PHARMACEU/ADR is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for ASLAN PHARMACEU/ADR.

What price target have analysts set for ASLN?

3 brokers have issued 12-month target prices for ASLAN PHARMACEU/ADR's shares. Their forecasts range from $5.00 to $8.00. On average, they anticipate ASLAN PHARMACEU/ADR's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 530.2% from the stock's current price. View analysts' price targets for ASLAN PHARMACEU/ADR.

Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?

Media stories about ASLN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutASLAN PHARMACEU/ADR.

Who are some of ASLAN PHARMACEU/ADR's key competitors?

What other stocks do shareholders of ASLAN PHARMACEU/ADR own?

Who are ASLAN PHARMACEU/ADR's key executives?

ASLAN PHARMACEU/ADR's management team includes the following people:
  • Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
  • Mr. Kiran Asarpota, VP of Fin. (Age 40)
  • Charlie Hsu, Investor Relations Director
  • Mr. Ben Goodger, Gen. Counsel (Age 56)
  • Chi-Chin Wang, IR & Corp. Devel. Director

When did ASLAN PHARMACEU/ADR IPO?

(ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN PHARMACEU/ADR's stock symbol?

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

Who are ASLAN PHARMACEU/ADR's major shareholders?

ASLAN PHARMACEU/ADR's stock is owned by a variety of institutional and retail investors. Top institutional investors include Marshall Wace LLP (0.30%), Bank of America Corp DE (0.25%), Virtu Financial LLC (0.17%) and Renaissance Technologies LLC (0.05%).

Which institutional investors are buying ASLAN PHARMACEU/ADR stock?

ASLN stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Virtu Financial LLC, and Renaissance Technologies LLC.

How do I buy shares of ASLAN PHARMACEU/ADR?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ASLAN PHARMACEU/ADR's stock price today?

One share of ASLN stock can currently be purchased for approximately $1.01.

How big of a company is ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR has a market capitalization of $32.21 million and generates $3 million in revenue each year. The company earns $-47,070,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.  View additional information about ASLAN PHARMACEU/ADR.

What is ASLAN PHARMACEU/ADR's official website?

The official website for ASLAN PHARMACEU/ADR is http://aslanpharma.com/.

How can I contact ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]


MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  164 (Thanks for Voting!)
Underperform Votes:  194 (Thanks for Voting!)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Channel Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel